The majority of life-threatening fungal infections are caused by the well-known opportunistic pathogens
Candida albicans,
Aspergillus fumigatus, and
Cryptococcus neoformans, with the latter being associated frequently with severe mycoses in AIDS patients (
22,
30). Candidiasis remains the major cause of invasive fungal infections in immunocompromised patients, and in recent years, an impressive increase in mortality rate due to candidemia by non-
C. albicans Candida species has been noted (
2,
6,
15,
20,
24). It has been suggested that the widespread use of azoles in clinical settings could have contributed to changing the etiology of
C. albicans candidemia toward non-
C. albicans species, which now account for more than 50% of systemic
Candida infections (
2,
6,
15). Rapid diagnosis of these mycoses is crucial for prompt management of infection with tailored antifungal treatments. However, conventional laboratory methods for identification of fungal pathogens, though continuously improving, are still time-consuming and therefore often inadequate for ensuring early targeted therapy, especially for uncommon or newly identified fungal species. Unlike what is currently available for bacteria, molecular approaches for the identification of pathogenic fungi have been held back so far due to the lack of a robust sequence data bank. However, several DNA-based methods have been introduced and have improved the identification of fungal pathogens and shortened the time required for their detection (
3,
12,
13,
19,
21,
26). Most molecular procedures allow the identification of one or a few species at a time (
3,
12,
13), thus resulting in a high cost if all relevant species must be considered. An ideal approach to overcome this limitation is given by the application of DNA microarray technology, which may enable discrimination of a wide range of pathogens in a single assay. The panmicrobial oligonucleotide array developed by Palacios and colleagues (
23) was designed mainly to produce a staged strategy for molecular surveillance and discovery of emerging pathogens, as it covers detection of viruses, bacteria, fungi, and parasites. However, in the case of fungi, the panmicrobial chip predominantly allows genus identification rather than fungal species discrimination. It should be noted that rapid identification of pathogenic fungi at the species level is relevant in medical practice, as fungemia and other fungal symptomatic infections are emerging as a leading cause of morbidity and mortality in the general patient population, especially for hospitalized cancer and major surgical patients (
15). A DNA microarray specifically developed by Leinberger and colleagues (
18) for detecting fungal pathogens enabled discrimination of the 12 most common pathogenic
Candida and
Aspergillus organisms at the species level, and the array developed by Huang and colleagues (
11) enlarged to 20 the number of identified species, which are representative of eight different genera. Nevertheless, neither system encompasses oligonucleotide probes for detection/identification of emerging fungi increasingly reported to be responsible for invasive or other symptomatic infections, such as
Candida famata,
Candida kefyr,
Trichosporon cutaneum,
Fusarium solani, and
Penicillium marneffei (
5,
10,
24,
31); moreover, the probes designed to detect
Candida parapsilosis do not differentiate this species from two newly identified and closely related ones, i.e.,
Candida orthopsilosis and
Candida metapsilosis (
27), which were recently reported to cause mycoses in humans (
14,
28). Oligonucleotide probes effectively enabling simultaneous discrimination of these three species may be useful, since available conventional methods do not allow discrimination of
C. parapsilosis from
C. orthopsilosis and
C. metapsilosis (
26,
28).
This report describes the development of an up-to-date oligonucleotide array for the unambiguous identification of 24 fungi, allotted into 10 diverse genera, including (i) species involved in invasive infections and frequently exhibiting a drug-resistant phenotype, such as
Candida glabrata,
Candida krusei, and
Aspergillus terreus (
17,
24,
25); (ii) emerging fungal pathogens, such as
C. famata,
C. kefyr,
Trichosporon cutaneum, or molds such as
Fusarium solani and
Penicillium marneffei; and (iii) the newly defined species
C. orthopsilosis and
C. metapsilosis. The oligonucleotide probes used in this microarray are complementary to the sequence variation in the internal transcribed spacer 1 and 2 (ITS1 and ITS2) region of each species. Direct labeling of PCR products is not required, and signals for fungal species identification are based on the arrayed-primer extension (APEX) technique, which has been applied successfully to discriminate natural variants of human papillomavirus type 16, to identify germ line mutations in beta-thalassemia, and for single-nucleotide polymorphism genotyping (
4,
7,
8,
16). The specificity and reproducibility of the array were validated with reference strains, and its application was tested with blinded clinical isolates.